Medigen Vaccine Biologics Corp’s (高端疫苗) phase 3 clinical trials for an enterovirus 71 (EV71) vaccine completed the multi-regional, multi-central data “unblinding” yesterday, with the results, including safety, immunogenicity and efficacy, meeting its expectations.
The company would compile a final analysis report as soon as possible, and apply for the new drug certificate from domestic and foreign drug authorities in the third quarter, Medigen said in a Taiwan Stock Exchange filing yesterday.
Its phase 3 trials were conducted in Taiwan and Vietnam with 3,049 participants ranging from two months old to six years old, Medigen said.
Photo: Sam Yeh, AFP
The company enrolled its first participant for the phase 3 trials in April 2019 and completed the enrollment of all participants in December that year, it said.
Participants were recruited in a randomized, double-blinded and placebo-controlled study, it added.
Participants were divided into three age groups: two months to six months old, six months to two years old, and two years to six years old, Medigen said.
The number of infants from two months to six months old accounted for 25 percent of all participants, it said.
The results showed the drug’s safety and tolerance were good, even for young participants, and there was no significant difference in safety and tolerance between participants who were given the vaccine and those who received a placebo, the company said.
As for immunogenicity, results showed that the seroprotection rates 28 days, six months and one year after two EV71 vaccination doses were higher than health authorities’ requirements, it said. The seroprotection rates refer to the degree of antibody prevalence.
In terms of efficacy, Medigen said that the experimental drug offered statistically significant protection against the enterovirus under the Poisson regression model.
As enterovirus infections are popular in Taiwan, China and Southeast Asia, the company hopes its vaccine can hit the market soon, as there are no EV71 vaccine products available in other parts of the world, except for China.
At present, only three Chinese manufacturers have launched enterovirus vaccines to be marketed locally in China, Medigen said.
Those vaccines are suitable for children over the age of six months, it said.
In 2018, the market sales of China’s EV71 vaccines reached more than NT$30 billion (US$1.08 billion), and about 21 million doses were sold per year on average in the past three years, Medigen said.
The company on June 10 reported positive results from an interim analysis of phase 2 trials for its COVID-19 vaccine. It has applied to the Food and Drug Administration for emergency use authorization and is preparing to conduct phase 3 trials abroad.
An index launched a year ago to give investors greater exposure to China’s Internet giants is now the world’s worst-performing major technology gauge. The Hang Seng Tech Index has been on a roller-coaster ride in the past 12 months. The gauge, which marks its first anniversary on Tuesday, was up 59 percent at its February peak, but has since seen more than US$551 billion in market value wiped out amid Beijing’s clampdown on the sector. That has reduced its gain to nearly 6 percent, compared with more than 40 percent for the MSCI World Information Technology Index and the NASDAQ-100 Index. The
Taiwan should protect its vaccine supply chain and invest in vaccine development after seeing how the COVID-19 pandemic has inflicted tremendous social and economic losses worldwide, Sanofi Pasteur Hong Kong & Taiwan general manager Philip Ho said in an interview this week. “When you look at the trillions of dollars that countries have lost, parents who are forced to stay at home with their children and various restrictions imposed following a nationwide lockdown, we really see what we are losing compared with what we can benefit from vaccination,” Ho said. While the government has been trying to secure vaccines since the middle
The next target for China’s cybersecurity crackdown is to be the pools of data collected by the latest generation of vehicles. This approach risks Beijing shooting itself in the foot, and jeopardizing its ambitious plans to lead the global race for electric and autonomous vehicles. China wants to have control over the information vehicles have about their drivers, the roads they traverse, and the faces and voices they pass, according to a draft law on data-security management for the automotive industry issued in May. It seeks to ensure manufacturers across the auto supply chain keep data in the country and pass
EDUCATION AS WELFARE: New regulations threaten to upend the lucrative private education sector that teaches the public school curriculum to paying families China unveiled a sweeping overhaul of its US$100 billion education tech sector, banning companies that teach the school curriculum from earning profit, raising capital or going public. Beijing on Saturday published an array of regulations that together threaten to overturn the sector and jeopardize billions of dollars in foreign investment. Companies that teach school subjects can no longer accept overseas investment, which could include capital from the offshore registered entities of Chinese firms, according to a notice released by the Chinese State Council. Those in violation of that rule must take steps to rectify the situation, the country’s most powerful administrative